KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $1.4 billion.

  • Recursion Pharmaceuticals' Liabilities and Shareholders Equity rose 92.64% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 billion, marking a year-over-year increase of 101.03%. This contributed to the annual value of $1.4 billion for FY2024, which is 121.60% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Liabilities and Shareholders Equity of $1.4 billion as of Q3 2025, which was up 7.46% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $1.4 billion during Q4 2024, and its lowest value of $271.9 million during Q1 2021.
  • Its 3-year average for Liabilities and Shareholders Equity is $917.7 million, with a median of $726.5 million in 2024.
  • In the last 5 years, Recursion Pharmaceuticals' Liabilities and Shareholders Equity spiked by 170.03% in 2022 and then declined by 14.56% in 2023.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Liabilities and Shareholders Equity stood at $610.3 million in 2021, then climbed by 14.90% to $701.3 million in 2022, then declined by 6.79% to $653.7 million in 2023, then spiked by 121.60% to $1.4 billion in 2024, then spiked by 92.64% to $1.4 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.4 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.3 billion for Q1 2025.